Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system https://t.co/w216RUI7CK https://t.co/mmyESCUzud

New Research: Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system: Background Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits… #immunology ht